Gold Prices Rebound in Asia Amid Iran War Ceasefire Hopes 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Asian Stocks Mixed in March 2026 Amid Iran War Fears and Tech Selloff 
U.S. Trade Rep Dismisses WTO's Future Role After Failed Cameroon Summit 
Oil Prices Surge to Record Monthly Highs as Middle East War Rattles Global Markets 
Goldman Sachs Sees Value in European Real Estate Stocks Despite Sharp Selloff 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Oil Prices Climb as Middle East Conflict Keeps Supply Risks Elevated 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
South Korea's Exports Hit Record High in March on AI-Driven Chip Demand 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
China Manufacturing PMI Hits 12-Month High Amid Energy Price Concerns 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
U.S. Dollar Posts Strong Monthly Gain Amid Middle East Conflict Despite Late Dip 
Lotte Biologics has inked a memorandum of understanding (MOU) with Roche Diagnostics to bolster its Contract Development and Manufacturing Organization (CDMO) capabilities. This collaboration signifies major diagnostics, hardware, and automation advancements for Lotte's upcoming Korean production plants.
On Wednesday, Aug. 9, Lotte Biologics said it will work with Roche Diagnostics to improve the productivity and quality of its productions. The company said they would also team up to establish hardware and automation systems for Lotte's upcoming production plants in Korea, as per Korea Joongang Daily.
The MOU was signed at Roche Diagnostics CustomBiotech Center in Penzberg, Germany. Lotte Biologics' chief executive officer, Richard Lee; Roche Diagnostics CustomBiotech's vice president, Rainer Mueller; and Roche Diagnostics Korea's general manager, Kit Tang, were all present at the signing ceremony.
With the deal in place, Lotte Biologics aims to amplify its credibility with future global clients. The agreement will also serve as the forefront to underpin and shore up Roche Diagnostics' supply network in the Asian market. This will also give better treatment access to patients around the world.
"Through this MOU, we plan to enhance the production process capabilities of our Korean Mega Plant in collaboration with Roche Diagnostics," Lotte Biologics chief Richard Lee said in a press release. "Through synergy with Roche Diagnostics, an industry leader in the in vitro diagnostic field, LOTTE hopes to improve the efficiency of its operations at the forthcoming Korean Mega Plant, simultaneously augmenting the quality of our manufacturing and fulfilling customer needs."
Finally, Business Korea reported that Lotte Biologics and Roche Diagnostics will cooperate on various business fronts, including installing automation systems at the former's Mega Plants that will be built in Korea. The latter will also provide technical consulting and equipment support for the facilities.
Photo by: Lotte Biologics Newsroom
